ALLOGENE THERAPEUTICS INC
NASDAQ: ALLO (Allogene Therapeutics, Inc.)
Last update: 11 hours ago2.09
0.05 (2.45%)
| Previous Close | 2.04 |
| Volume | 4,963,963 |
| Price / Sales | 111.88 |
| Price / Book | 1.62 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -1.22 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 23.07% |
| Current Ratio (MRQ) | 9.71 |
| Operating Cash Flow (TTM) | -197.33 M |
| Levered Free Cash Flow (TTM) | -96.65 M |
| Return on Assets (TTM) | -28.92% |
| Return on Equity (TTM) | -59.60% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Allogene Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.67 |
|
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC). |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 17.70% |
| % Held by Institutions | 81.75% |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |